WYE-125132 (also known as WYE 132) is a novel, highly potent, selective and ATP-competitive inhibitor of mTOR (mammalian target of rapamycin) with potential antitumor activity.

mTOR inhibitor-1 is a novel mTOR pathway inhibitor which can suppress cells proliferation and inducing autophagy.

PQR620 is a novel, potent, selective and brain penetrant inhibitor of mTORC1/2 which plays a fundamental role in cell proliferation, differentiation, growth and survival.

Vistusertib (formerly AZD-2014) is a novel, potent, orally bioavailable and ATP competitive inhibitor of mTOR (mammalian target of rapamycin) with potential antitumor activity.

GDC-0349(also known as RG-7603) is a novel, potent, orally bioavailable and selective ATP-competitive inhibitor of mTOR (mammalian target of rapamycin) with potential antitumor activity.

WYE-354 (WYE 354) is a novel, potent, specific, cell-permeable and ATP-competitive mTOR (mammalian target of rapamycin) inhibitor with potential anticancer/antitumor activity.

L-Leucine-1-13C is the 13C-labeled form of L-Leucine, which is an essential amino acid used in the biosynthesis of proteins.

Torkinib (also known as PP242) is a novel, potent and selective ATP-competitive mTOR (mammalian target of rapamycin) inhibitor with potential anticancer activity.

Desmethyl-VS-5584 is a novel and potent PI3K/mTOR kinase inhibitor.

XL388 is a novel, highly potent, selective, oral, ATP-competitive inhibitor of mTOR (mammalian target of rapamycin) with potential antitumor activity.